跳至主要内容
临床试验/IRCT20220220054079N1
IRCT20220220054079N1招募中3 期

Effect of deferoxamine injection on the Glasgow Outcome Scale in patients with severe traumatic brain injury: a double-blind, randomized controlled clinical trial

Shiraz University of Medical Sciences0 个研究点目标入组 68 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
68

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • Patients with severe traumatic brain injury
  • Patients with pure traumatic brain injury: having a score of less and equal to 3 on the Brain Abbreviated Injury scale; and a score of less than 3 on the Extracranial Abbreviated Injury scale

排除标准

  • Allergy to deferoxamine mesylate
  • Serum creatinine more than 2 mg/dL
  • Hemoglobin less than 7 g/L, or patients requiring transfusion therapy
  • A Glasgow Coma Scale score of 3 or 4 with bilateral fixed and dilated pupils
  • A known history of intracranial diseases
  • A known history of thrombocytopenia (platelet count less than 50×109/L)
  • Concurrent use of anti-coagulant or anti-platelet agents or history of coagulation disorders (international normalized ratio more than 1.4)
  • Concurrent use of iron supplements or prochlorperazine
  • Impaired hearing
  • Pregnant or lactating women
  • History of cardiopulmonary arrest and resuscitation
  • Blood disorders (e.g. thalassemia, iron deficiency anemia)
  • GFR less than 50 ml/min
  • History of heart failure
  • History of liver disease

研究者

相似试验

Deferoxamine in severe traumatic brain injury | 临床试验